Exact Mass: 331.0546064
Exact Mass Matches: 331.0546064
Found 49 metabolites which its exact mass value is equals to given mass value 331.0546064,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Piroxicam
Piroxicam is only found in individuals that have used or taken this drug. It is a cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BC - Antiinflammatory agents, non-steroids D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents KEIO_ID P068; [MS2] KO009199 D004791 - Enzyme Inhibitors KEIO_ID P068
2-Methyl-1,1,4-trioxo-N-(2-pyridinyl)-3H-1$l^{6},2-benzothiazine-3-carboxamide
Zonampanel
2-(Methylsulfonyl)-3-(6-phenyl-2,3-dihydroimidazo[2,1-b][1,3]thiazol-5-yl)acrylonitrile
piroxicam
A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling. M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BC - Antiinflammatory agents, non-steroids D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
N-(2,4-Dinitrophenyl)-DL-methionine sulfoxide
C11H13N3O7S (331.04741880000006)
3-[3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]benzoic acid
5-Bromo-2-((tert-Butyldimethylsilyloxy)methyl)-3-methoxypyridine
tert-butyl N-[3-bromo-1-(3-fluorophenyl)propyl]carbamate
C14H19BrFNO2 (331.05831059999997)
tert-butyl N-[3-bromo-1-(4-fluorophenyl)propyl]carbamate
C14H19BrFNO2 (331.05831059999997)
2-[2-[4-(2-methyl-1,3-thiazol-4-yl)anilino]-1,3-thiazol-4-yl]acetic acid
Glymidine sodium
C13H14N3NaO4S (331.06026840000004)
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
tert-butyl N-[3-bromo-1-(2-fluorophenyl)propyl]carbamate
C14H19BrFNO2 (331.05831059999997)
3-(4-CHLORO-BENZENESULFONYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
1-cyclopropyl-8-(difluoromethoxy)-6,7-difluoro-4-oxoquinoline-3-carboxylic acid
C14H9F4NO4 (331.04676820000003)
5-(benzyloxy)-8-(2-chloroacetyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
6-benzyloxy-8-(2-chloro-acetyl)-4H-benzo[1,4]oxazin-3-one
N-(3-CHLOROPHENYL)-2-(5-(3-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL)ACETAMIDE
Zonampanel
C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant C26170 - Protective Agent > C1509 - Neuroprotective Agent Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.
2-Chloro-5-(3,5-dimethylpiperidinosulphonyl)benzoic acid
2-Methyl-1,1,4-trioxo-N-(2-pyridinyl)-3H-1$l^{6},2-benzothiazine-3-carboxamide
4-[(4-Phenyl-2-thiazolyl)amino]-benzenesulfonamide
(5-Hydroxy-6-Methyl-4-{[(3-Oxo-2,3-Dihydro-1,2-Oxazol-4-Yl)amino]methyl}pyridin-3-Yl)methyl Dihydrogen Phosphate
[5-Hydroxy-6-Methyl-4-({[(4e)-3-Oxo-1,2-Oxazolidin-4-Ylidene]amino}methyl)pyridin-3-Yl]methyl Dihydrogen Phosphate
8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D004791 - Enzyme Inhibitors > D000067956 - Adenylyl Cyclase Inhibitors
Laricitrin(1-)
The conjugate base of laricitrin arising from deprotonation of the 3-OH group; major species at pH 7.3.
2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-6-methoxy-4-oxochromen-5-olate
4-(4-chlorophenyl)-3-[(4-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione
N-[4-(3-methoxyphenyl)-2-thiazolyl]-2-thiophenecarbohydrazide
2-(2-Chlorophenyl)-2-oxoethyl 3-(acetylamino)benzoate
5-[(1,3-Benzodioxol-5-ylamino)methylidene]-1-cyclopropyl-2-sulfanylidene-1,3-diazinane-4,6-dione
2-[2-(4-Methoxyphenyl)-2-oxoethyl]-1,1-dioxo-1,2-benzothiazol-3-one
N-[4-methyl-5-[2-(2-pyridinylamino)-4-thiazolyl]-2-thiazolyl]acetamide
2-(3-thiophenyl)acetic acid [2-oxo-2-(3-oxo-4H-1,4-benzoxazin-6-yl)ethyl] ester
N-[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]-1-methyl-2-pyrrolecarboxamide
(2Z)-2-[(2,4-dimethoxyphenyl)methylidene]-6-methyl-[1,3]thiazolo[3,2-b][1,2,4]triazine-3,7-dione
3-(4-chlorophenyl)-N-cyclopropyl-1-methyl-5-thieno[2,3-c]pyrazolecarboxamide
2-[2-(3-bromophenoxy)ethyl]-3,4-dihydro-1H-isoquinoline
SKF-83566
SKF-83566 is a potent,?blood-brain permeable and orally active D1-like dopamine receptor (D1DR)?antagonist and a weaker competitive antagonist at the vascular 5-HT2?receptor (Ki=11 nM)[1][3]. SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50?of 5.7 μM[2]. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta[4]. SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation[5].